Shaun Eintracht

Dr. Shaun Eintracht


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 June 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
Ivan BruknerIvan Brukner
Ivan Brukner
ARAlex Resendes
Alex Resendes
SEShaun Eintracht
Shaun Eintracht
APAndreas Ioannis Papadakis
Andreas Ioannis Papadakis
MOMatthew Oughton
Matthew Oughton
Sample Adequacy Control (SAC) has critical analytical, clinical and epidemiological value that increases confidence in a negative test result. The SAC is an integral qPCR assay control, which ensures that all pre-analytical and analytical steps are adequate for accurate testing and reporting. As such, a negative SAC with a negative result on pathogen screen specifies that the result should be reported as inconclusive instead of negative. Despite this, many regulatory approved tests do not incorporate SAC into their assay design. Herein, we emphasize the universal value of SAC and offer for the first time, a simple technical strategy to introduce non-competitive SAC which does not interfere with the limit of detection for the screened pathogen. Integration of SAC can provide key benefits towards identifying, isolating, quarantining and contact tracing infected individuals and in turn can improve worldwide efforts in infection control.

16 December 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
MOMatthew Oughton
Matthew Oughton
Ivan BruknerIvan Brukner
Ivan Brukner
SEShaun Eintracht
Shaun Eintracht
APAndreas Ioannis Papadakis
Andreas Ioannis Papadakis
Alan SpatzAlan Spatz
Alan Spatz
ARAlex Resendes
Alex Resendes
Respiratory screening assays lacking Sample Adequacy Controls (SAC) may result in inadequate sample quality and thus false negative results. The non-adequate samples might represent a significant proportion of the total performed tests, thus resulting in sub-optimal infection control measures with implications that may be critical during pandemic times. The quantitative sample adequacy threshold can be established empirically, measuring the change in the frequency of positive results, as a function of the numerical value of “sample adequacy”. Establishing a quantitative threshold for SAC requires a big number/volume of tests to be analyzed in order to have a statistically valid result. Herein, we are offering for the first time clear clinical evidence that a subset of results, which did not pass minimal sample adequacy criteria, have a significantly lower frequency of positivity compared with the “adequate” samples. Flagging these results and/or re-sampling them is a mitigation strategy, which can dramatically improve infection control measures.

30 June 2026 in LabMed
Verified
Journal Article
Open access
PDF file
Ivan BruknerIvan Brukner
Ivan Brukner
SEShaun Eintracht
Shaun Eintracht
MOMatthew Oughton
Matthew Oughton
Sample adequacy control (SAC) is a validated specimen-specific marker or metric, threshold, and reporting rule used to decide whether a negative molecular result is supported by the submitted specimen. SAC is not simply a cell-count or biomass check. Depending on specimen type and target, an unsupported negative result may reflect insufficient or nonrepresentative material, adequacy-marker degradation, inefficient transfer or extraction, matrix-associated inhibition, or mismatch between marker and anatomical compartment. SAC is therefore best understood as an integrated specimen-process adequacy control for negative-result interpretation. Its result should be reported as valid, borderline, or invalid for the intended negative interpretation, not as detected/not detected like the disease-specific biomarker. This perspective synthesizes quantitative polymerase chain reaction (qPCR) control guidance, preanalytical-quality literature, respiratory and enteric sampling studies, human papillomavirus (HPV) evidence, cartridge-assay precedents, and decentralized workflows. Direct prospective evidence that SAC improves patient or epidemiologic outcomes remains limited; available evidence is outcome-adjacent or operational, including HPV cellularity-control associations, Chlamydia trachomatis/Neisseria gonorrhoeae (CT/NG) and Ebola cartridge precedents, respiratory workflows showing lower pathogen positivity at higher SAC quantification cycle (Cq) strata, and reporting rules that change validity or recollection decisions. We propose a risk-based framework for selecting, validating, reporting, and monitoring SAC, with particular value in direct-amplification, point-of-care, and self-collection workflows where preanalytical failures affect negative-result interpretation.

3 November 2025 in Canadian Journal of Diabetes
Verified
Journal Article
Open access
SASanaz Azizi
Sanaz Azizi
AMAgnieszka Majdan
Agnieszka Majdan
RBRachel Bond
Rachel Bond
NGNatasha Garfield
Natasha Garfield
SMSara Meltzer
Sara Meltzer
TPTricia M. Peters
Tricia M. Peters
To compare two gestational diabetes mellitus (GDM) diagnostic thresholds in relation to large for gestational age (LGA) status and secondary adverse pregnancy outcomes. This retrospective cohort study examined 840 pregnant women who underwent two-step GDM screening at two hospital centres in Montreal that use distinct GDM diagnostic thresholds. At the second step of GDM screening, one centre used glucose thresholds suggested by the Diabetes Canada preferred approach and the other centre used the lower International Association of Diabetes and Pregnancy Study Group thresholds. We defined mild hyperglycemia (MH) as intermediate glucose values that were diagnostic of GDM at one centre but not the other (fasting plasma glucose [PG] 5.1-5.2 mmol/L; 1hPG 10-10.5 mmol/L; or 2hPG 8.5-8.9 mmol/L). We conducted multivariable linear and logistic regression analyses to evaluate outcomes for women with untreated or treated MH compared to those diagnosed with GDM by higher glucose thresholds within the same centre and also explored differences between centres. The odds of LGA offspring were three-fold higher (aOR 3.01, 95% CI 1.47, 6.19) among women with untreated MH compared to women treated for GDM at the same centre. Also, the odds of macrosomia were over two-fold higher comparing treated MH with GDM. In addition, untreated compared with treated MH had lower odds of induction of labour (aOR 0.28, 95% CI 0.11, 0.70). Failure to optimally treat MH during pregnancy is associated with fetal overgrowth and may affect obstetrical management.